ClinicalTrials.gg
Active, not recruitingNCT07288203Updated Oct 1, 2026

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

A Phase 2 interventional study of Lifileucel in Melanoma (Skin Cancer), Unresectable Melanoma and Metastatic Melanoma, sponsored by Iovance Biotherapeutics, Inc.. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 1, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing lifileucel in Melanoma — 4 open to participants now, 7 under way, 1 of them phase 3. lifileucel · Melanoma.

Planned enrollment
5th of 13
24 · median 10
Started
2025
the only one that year
Phase 2
4 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
4 of 13
Iovance Biotherapeutics, Inc.

Among the 13 studies testing lifileucel in Melanoma, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 2, and was the 12th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

4 of the 13 studies testing lifileucel in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lifileucel

lifileucel: first FDA approval 2024 (AMTAGVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lifileucel in Melanoma, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma

Read the detailed description

This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor

± a MEK inhibitor

03

Conditions studied

  • Melanoma (Skin Cancer)
  • Unresectable Melanoma
  • Metastatic Melanoma

Keywords

  • Tumor Infiltrating Lymphocytes
  • TIL
  • Metastatic Melanoma
  • Unresectable Melanoma
  • Cell Therapy
  • Cellular Immuno-therapy
  • IL-2
  • Non-myeloablative lymphodepletion (NMALD)
  • Melanoma
  • Lifileucel
  • Skin Cancer
  • LN-144
  • BRAF v600
  • BRAF/MEK
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or melanoma.
  • The participant has an performance status of 0 or 1 and an estimated of > 6 months.
  • The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
  • Participant must have at least one as defined by 1.1 following tumor resection.
  • Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
  • Participants of or those with partners of childbearing potential must be willing to practice an approved method of highly effective .
  • Participants must have adequate organ function.
  • Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

Exclusion criteria

Exclusion Criteria:

  • Participant has melanoma of uveal/ocular origin.
  • Participant has symptomatic untreated .
  • Participant has active uveitis that requires active treatment.
  • Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
  • Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
  • Participant had another primary within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
  • Participant has a history of allogeneic cell or organ transplant.
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

Other protocol defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Lifileucel

    Biological: Lifileucel

Interventions

  • BiologicalLifileucel

    A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.

    Also known as: LN-144

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators

    Time frame: 12 months

Secondary outcomes

  1. Complete Response Rate

    To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators

    Time frame: 12 months

  2. Duration of Response

    To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators

    Time frame: 12 months

  3. Disease Control Rate

    To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators

    Time frame: 12 months

  4. Progression-Free Survival

    To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators

    Time frame: 12 months

  5. Overall Survival

    To evaluate the efficacy of lifileucel as measured by OS

    Time frame: 18 months

  6. Adverse Events

    To demonstrate safety and tolerability of lifileucel

    Time frame: 18 months

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 25 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Dec 2032 → Dec 2027 and completion Dec 2033 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 17, 2025
StartActual
Nov 28, 2025
Primary completionEst.
Dec 2027was Dec 2032
CompletionEst.
Jun 2028was Dec 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2032→Dec 2027
Oct 1, 2026
Study completion
Dec 2033→Jun 2028
Oct 1, 2026
Enrollment
100→24
Oct 1, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedThe participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma and/or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
Oct 1, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameObjective Response Rate5 years → 12 months
  • DescriptionObjective Response Rate: how it is measured was reworded
Oct 1, 2026
Secondary outcomes
6 time frame changed, 5 removed, 4 description edited
What changed in the outcomes
  • RemovedObjective Response RateTime frame: 5 years
  • RemovedComplete Response RateTime frame: 5 years
  • RemovedDuration of ResponseTime frame: 5 years
  • RemovedDisease Control RateTime frame: 5 years
  • RemovedProgression-Free SurvivalTime frame: 5 years
  • Time frameComplete Response Rate5 years → 12 months
  • Time frameDuration of Response5 years → 12 months
  • Time frameDisease Control Rate5 years → 12 months
  • Time frameProgression-Free Survival5 years → 12 months
  • Time frameOverall Survival5 years → 18 months
  • Time frameAdverse Events5 years → 18 months
  • DescriptionComplete Response Rate: how it is measured was reworded
  • DescriptionDisease Control Rate: how it is measured was reworded
  • DescriptionDuration of Response: how it is measured was reworded
  • DescriptionProgression-Free Survival: how it is measured was reworded
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Dec 2032→Dec 2027
    Study completion Dec 2033→Jun 2028
    Enrollment 100→24
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedThe participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma and/or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameObjective Response Rate5 years → 12 months
    • DescriptionObjective Response Rate: how it is measured was reworded
    Secondary outcomes 6 time frame changed, 5 removed, 4 description edited
    What changed in the outcomes
    • RemovedObjective Response RateTime frame: 5 years
    • RemovedComplete Response RateTime frame: 5 years
    • RemovedDuration of ResponseTime frame: 5 years
    • RemovedDisease Control RateTime frame: 5 years
    • RemovedProgression-Free SurvivalTime frame: 5 years
    • Time frameComplete Response Rate5 years → 12 months
    • Time frameDuration of Response5 years → 12 months
    • Time frameDisease Control Rate5 years → 12 months
    • Time frameProgression-Free Survival5 years → 12 months
    • Time frameOverall Survival5 years → 18 months
    • Time frameAdverse Events5 years → 18 months
    • DescriptionComplete Response Rate: how it is measured was reworded
    • DescriptionDisease Control Rate: how it is measured was reworded
    • DescriptionDuration of Response: how it is measured was reworded
    • DescriptionProgression-Free Survival: how it is measured was reworded
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07288203
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Nov 28, 2025
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifileucel

Start the discussion